Application of the Nivolumab in the treatment of advanced non-small cell lung cancer

Lung cancer has the highest morbidity and mortality among malignant tumors in our country. The treatment researches related to non-small cell lung cancer (NSCLC) such as targeted therapy and immunotherapy are the research hotspots in recent years. Nivolumab is the first programmed death-1 (PD-1) inhibitor which is allowed to enter clinical trials, and it is also the first approved drug for tumor immunotherapy in China. In June 2018, Nivolumab injection was marketed in China, and it was used in the second-line treatment for the patients with advanced NSCLC, opened up a new era of the lung cancer treatment in our country. Review the clinical research related to the Nivolumab and NSCLC, summarizing usage, dosage, adverse reactions, will provide a help for clinical application, bring more benefits for patients at the same time. Key words: Carcinoma, non-small-cell lung; Immunotherapy; Nivolumab